CLAIMS

1. An isolated human antibody or antigen-binding fragment thereof that specifically binds to Hemolysin A, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 142; and a light chain variable region (LCVR) comprising three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a LCVR comprising the amino acid sequence set forth in SEQ ID NO: 150.

2. The isolated human antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 142.

3. The isolated human antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 150.

4. The isolated human antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises: (a) a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 142; and (b) a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 150.

5. The isolated human antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises:

(a) a HCDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 144;

(b) a HCDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 146;

(c) a HCDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 148;

(d) a LCDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 152;

(e) a LCDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 154; and

(f) a LCDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 156.

6. The isolated human antibody or antigen-binding fragment of claim 4, which is an antibody.

7. The antibody of claim 6, wherein the HCVR is linked to a human gamma-1 heavy chain constant region.

8. The antibody of claim 7, wherein the LCVR is linked to a human light chain kappa constant region.

9. A method for making an antibody or antigen-binding fragment thereof of claim 1, comprising:

(i) introducing one or more polynucleotides encoding a light chain variable region comprising three light chain CDRs of said antibody or antigen-binding fragment and a heavy chain variable region comprising three heavy chain CDRs of said antibody or antigen-binding fragment into a host cell; and

(ii) culturing the host cell in a growth medium under conditions favorable to expression of the polynucleotide(s).

10. An injection device or vessel comprising an antibody of claim 6.

11. A pharmaceutical composition comprising the antibody according to claim 6, and a pharmaceutically acceptable carrier or diluent.

12. The pharmaceutical composition of claim 11 comprising an additional therapeutic agent which is an antibiotic, a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid, an additional anti-Hemolysin A antibody, or prednisone.

13. The method of claim 9, further comprising isolating the antibody or antigen-binding fragment, which comprises the three light chain CDRs and the three heavy chain CDRs, from the host cell or medium in which the host cell is grown.

14. The method of claim 9, wherein the antibody or antigen-binding fragment comprises: (a) a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 142; and (b) a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 150.

15. The method of claim 9, wherein the antibody or antigen-binding fragment comprises:

(a) a HCDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 144;

(b) a HCDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 146;

(c) a HCDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 148;

(d) a LCDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 152;

(e) a LCDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 154; and

(f) a LCDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 156.

16. The method of claim 14, wherein the antibody or antigen-binding fragment is an antibody.

17. The method of claim 16, wherein the HCVR is linked to a human gamma-1 heavy chain constant region.

18. The method of claim 17, wherein the LCVR is linked to a human light chain kappa constant region.

19. An injection device or vessel comprising an antibody or antigen-binding fragment of claim 1.

20. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1, and a pharmaceutically acceptable carrier or diluent.